Global RNA Vaccines Market Insights, Research, Forecast to 2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 113

Report ID: 324167

RNA is a rather versatile technology and offers a number of advantages. RNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes RNA especially attractive for vaccines and gene editing. RNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of RNA has greatly favored the development of in vivo transfection strategies.
RNA Vaccines & Therapeutics is in the development stage and there is no use in the market. The fastest research is Clinical phrase II, such as AGS-004 of Argos Therapeutics, SB-FIX, SB-318, SB-913 of Sangamo Therapeutics. The major application of RNA Vaccines & Therapeutics is for infectious disease, cancer and others. And infectious disease and cancer are the major applications.
The global RNA Vaccines market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the RNA Vaccines market based on company, product type, end user and key regions.

This report studies the global market size of RNA Vaccines in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of RNA Vaccines in these regions.
This research report categorizes the global RNA Vaccines market by top players/brands, region, type and end user. This report also studies the global RNA Vaccines market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology

Market size by Product
Individualized Cancer Treatment MRNA Vaccine
Infectious Disease Treatment MRNA Vaccine
Infection Prevention MRNA Vaccine
Market size by End User
Infectious Disease
Cancer
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global RNA Vaccines market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of RNA Vaccines market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global RNA Vaccines companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of RNA Vaccines submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of RNA Vaccines are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Doses). Both top-down and bottom-up approaches have been used to estimate and validate the market size of RNA Vaccines market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 RNA Vaccines Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global RNA Vaccines Market Size Growth Rate by Product
1.4.2 Individualized Cancer Treatment MRNA Vaccine
1.4.3 Infectious Disease Treatment MRNA Vaccine
1.4.4 Infection Prevention MRNA Vaccine
1.5 Market by End User
1.5.1 Global RNA Vaccines Market Size Growth Rate by End User
1.5.2 Infectious Disease
1.5.3 Cancer
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global RNA Vaccines Market Size
2.1.1 Global RNA Vaccines Revenue 2014-2025
2.1.2 Global RNA Vaccines Sales 2014-2025
2.2 RNA Vaccines Growth Rate by Regions
2.2.1 Global RNA Vaccines Sales by Regions
2.2.2 Global RNA Vaccines Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 RNA Vaccines Sales by Manufacturers
3.1.1 RNA Vaccines Sales by Manufacturers
3.1.2 RNA Vaccines Sales Market Share by Manufacturers
3.1.3 Global RNA Vaccines Market Concentration Ratio (CR5 and HHI)
3.2 RNA Vaccines Revenue by Manufacturers
3.2.1 RNA Vaccines Revenue by Manufacturers (2014-2019)
3.2.2 RNA Vaccines Revenue Share by Manufacturers (2014-2019)
3.3 RNA Vaccines Price by Manufacturers
3.4 RNA Vaccines Manufacturing Base Distribution, Product Types
3.4.1 RNA Vaccines Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers RNA Vaccines Product Type
3.4.3 Date of International Manufacturers Enter into RNA Vaccines Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global RNA Vaccines Sales by Product
4.2 Global RNA Vaccines Revenue by Product
4.3 RNA Vaccines Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global RNA Vaccines Breakdown Data by End User

6 North America
6.1 North America RNA Vaccines by Countries
6.1.1 North America RNA Vaccines Sales by Countries
6.1.2 North America RNA Vaccines Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America RNA Vaccines by Product
6.3 North America RNA Vaccines by End User

7 Europe
7.1 Europe RNA Vaccines by Countries
7.1.1 Europe RNA Vaccines Sales by Countries
7.1.2 Europe RNA Vaccines Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe RNA Vaccines by Product
7.3 Europe RNA Vaccines by End User

8 Asia Pacific
8.1 Asia Pacific RNA Vaccines by Countries
8.1.1 Asia Pacific RNA Vaccines Sales by Countries
8.1.2 Asia Pacific RNA Vaccines Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific RNA Vaccines by Product
8.3 Asia Pacific RNA Vaccines by End User

9 Central & South America
9.1 Central & South America RNA Vaccines by Countries
9.1.1 Central & South America RNA Vaccines Sales by Countries
9.1.2 Central & South America RNA Vaccines Revenue by Countries
9.1.3 Brazil
9.2 Central & South America RNA Vaccines by Product
9.3 Central & South America RNA Vaccines by End User

10 Middle East and Africa
10.1 Middle East and Africa RNA Vaccines by Countries
10.1.1 Middle East and Africa RNA Vaccines Sales by Countries
10.1.2 Middle East and Africa RNA Vaccines Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa RNA Vaccines by Product
10.3 Middle East and Africa RNA Vaccines by End User

11 Company Profiles
11.1 Moderna Therapeutics
11.1.1 Moderna Therapeutics Company Details
11.1.2 Company Business Overview
11.1.3 Moderna Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Moderna Therapeutics RNA Vaccines Products Offered
11.1.5 Moderna Therapeutics Recent Development
11.2 CureVac
11.2.1 CureVac Company Details
11.2.2 Company Business Overview
11.2.3 CureVac RNA Vaccines Sales, Revenue and Gross Margin (2014-2019)
11.2.4 CureVac RNA Vaccines Products Offered
11.2.5 CureVac Recent Development
11.3 Translate Bio
11.3.1 Translate Bio Company Details
11.3.2 Company Business Overview
11.3.3 Translate Bio RNA Vaccines Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Translate Bio RNA Vaccines Products Offered
11.3.5 Translate Bio Recent Development
11.4 BioNTech
11.4.1 BioNTech Company Details
11.4.2 Company Business Overview
11.4.3 BioNTech RNA Vaccines Sales, Revenue and Gross Margin (2014-2019)
11.4.4 BioNTech RNA Vaccines Products Offered
11.4.5 BioNTech Recent Development
11.5 Sangamo Therapeutics
11.5.1 Sangamo Therapeutics Company Details
11.5.2 Company Business Overview
11.5.3 Sangamo Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Sangamo Therapeutics RNA Vaccines Products Offered
11.5.5 Sangamo Therapeutics Recent Development
11.6 Argos Therapeutics
11.6.1 Argos Therapeutics Company Details
11.6.2 Company Business Overview
11.6.3 Argos Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Argos Therapeutics RNA Vaccines Products Offered
11.6.5 Argos Therapeutics Recent Development
11.7 In-Cell-Art
11.7.1 In-Cell-Art Company Details
11.7.2 Company Business Overview
11.7.3 In-Cell-Art RNA Vaccines Sales, Revenue and Gross Margin (2014-2019)
11.7.4 In-Cell-Art RNA Vaccines Products Offered
11.7.5 In-Cell-Art Recent Development
11.8 eTheRNA
11.8.1 eTheRNA Company Details
11.8.2 Company Business Overview
11.8.3 eTheRNA RNA Vaccines Sales, Revenue and Gross Margin (2014-2019)
11.8.4 eTheRNA RNA Vaccines Products Offered
11.8.5 eTheRNA Recent Development
11.9 Ethris
11.9.1 Ethris Company Details
11.9.2 Company Business Overview
11.9.3 Ethris RNA Vaccines Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Ethris RNA Vaccines Products Offered
11.9.5 Ethris Recent Development
11.10 Tiba Biotechnology
11.10.1 Tiba Biotechnology Company Details
11.10.2 Company Business Overview
11.10.3 Tiba Biotechnology RNA Vaccines Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Tiba Biotechnology RNA Vaccines Products Offered
11.10.5 Tiba Biotechnology Recent Development

12 Future Forecast
12.1 RNA Vaccines Market Forecast by Regions
12.1.1 Global RNA Vaccines Sales Forecast by Regions 2019-2025
12.1.2 Global RNA Vaccines Revenue Forecast by Regions 2019-2025
12.2 RNA Vaccines Market Forecast by Product
12.2.1 Global RNA Vaccines Sales Forecast by Product 2019-2025
12.2.2 Global RNA Vaccines Revenue Forecast by Product 2019-2025
12.3 RNA Vaccines Market Forecast by End User
12.4 North America RNA Vaccines Forecast
12.5 Europe RNA Vaccines Forecast
12.6 Asia Pacific RNA Vaccines Forecast
12.7 Central & South America RNA Vaccines Forecast
12.8 Middle East and Africa RNA Vaccines Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 RNA Vaccines Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer